Medicare Part D Coverage Gap (Donut Hole) Closes in 2020

March 26th, 2020 - Jared Staheli
Categories:   Medicare   Drugs|Pharmaceuticals|FDA  
0 Votes - Sign in to vote or comment.

The Medicare Part D coverage gap, also known as the “Donut Hole,” describes the period between post-deductible initial coverage (beneficiary responsible for 25% of the drug cost) and catastrophic coverage (beneficiary responsible for 5% of the drug cost). Initially, when Medicare Part D was first implemented in 2006, beneficiaries were responsible for 100% of the cost of the drugs in the coverage gap. When the Affordable Care Act (ACA) passed in 2010, one piece of the legislation aimed to close this coverage gap by 2020 by requiring drug manufacturers to provide a substantial discount on the cost of their drugs. In addition, the Bipartisan Budget Act of 2018 mandated the insurance plans cover a small portion (5%) of spending in the coverage gap. In 2019, the gap closed for brand-name medications - beneficiaries paid 25% of the cost all the way up to the point at which catastrophic coverage began. This year, generic medications will also reach that point, meaning that the coverage gap (from the beneficiary’s perspective) is now officially closed.

However, something to note as the coverage gap finally closes is that the point at which catastrophic coverage kicks in saw its highest ever increase due to the expiration of a provision of the ACA which limited these yearly increases. The catastrophic coverage amount has skyrocketed by nearly 20% to $6,350, up from $5,100 in 2019. Between 2018 and 2019, this increase was only 2%, in line with inflation. This increase reduces the benefits to Medicare beneficiaries that closing the coverage gap provides, but they are still in a much better position than in the pre-ACA days where they were on the hook for 100% of the costs in the gap. The table below outlines the 2020 picture for Part D coverage.


Out-of-Pocket Costs


100% of the cost


Initial Coverage

25% of the cost


Coverage Gap**

(both generic and brand-name drugs)

25% of the cost


Catastrophic Coverage

5% of the cost



$32.74/month +
any applicable
income-based premium****


* Both insurance plan spending and beneficiary out-of-pocket spending are included here
** The coverage gap still technically exists - but only from the perspective of the insurance plans and drug manufacturers who contribute to reduce the out-of-pocket costs for Medicare beneficiaries and effectively eliminate the gap
*** Both the manufacturer discount and beneficiary out-of-pocket spending are included here
****Income-related monthly adjustment amounts (IRMAA) are applied to beneficiaries with incomes above $87,000 if filing an individual return or $174,000 if filing a joint return

Though the closing of the coverage gap helps beneficiaries, the continued escalation of drug prices is leading to substantial increases in the number of beneficiaries crossing into catastrophic coverage territory. While different methods of addressing this issue are being explored, there is currently not a permanent fix that protects both Medicare beneficiaries and the fiscal sustainability of the Medicare program. The only long-term solution is to lower drug prices. As price increases continue to plague the healthcare marketplace, including Medicare, it’s time for a bipartisan solution.


Questions, comments?

If you have questions or comments about this article please contact us.  Comments that provide additional related information may be added here by our Editors.

Latest articles:  (any category)

​​Polysomnography Services Under OIG Scrutiny
September 2nd, 2021 - Raquel Shumway
The OIG conducted a study dated June 2019 wherein they indicated that there were approximately $269 million in overpayments for polysomnography services for the period of 2014 through 2015. According to the OIG “These errors occurred because the CMS oversight of polysomnography services was insufficient to ensure that providers complied with Medicare requirements and to prevent payment of claims that didn’t meet those requirements.” So what are those requirements?
Medicare Advantage - The Fastest Growing Government-Funded Program Undergoing Multiple Fraud Investigations
August 16th, 2021 - Aimee Wilcox, CPMA, CCS-P, CST, MA, MT, Director of Content
Medicare Advantage is the fastest growing form of government-funded healthcare and the rate of fraud within this segment has come under increased scrutiny. Funding is determined by the health status of each beneficiary; therefore, accurate coding based on detailed documentation makes the medical record vital to the process because some ...
Billing Dental Implants under Medical Coverage
August 12th, 2021 - Christine Woolstenhulme, QCC, QMCS, CPC, CMRS
Implants can be costly to the patient and the provider, and it is crucial to understand how to bill a patient’s medical insurance to ensure there is adequate coverage for the best treatment. Implants are commonly billed in a dental office under a patient’s medical benefits.    Implants could be considered ...
New Codes for COVID Booster Vaccine & Monoclonal Antibody Products
August 10th, 2021 - Wyn Staheli, Director of Research
New codes have been announced for the COVID-19 booster vaccine, Novavax vaccine, and monoclonal antibody treatment.
Medicare's ABN Booklet Revised
July 29th, 2021 - Wyn Staheli, Director of Research
The “Medicare Advance Written Notices of Non-coverage” booklet, published by CMS’s Medicare Learning Network, was updated. This article discusses the changes to this booklet regarding the use of the ABN.
Chronic Pain Coding Today & in the Future
July 19th, 2021 - Wyn Staheli, Director of Research
Properly documenting and coding chronic pain can be challenging. As is commonly the case with many conditions, over the years, there has been a shift in the identification of different types of pain, including chronic pain. Understanding where we are now and where we are going will help your organization prepare for the future by changing documentation patterns now.
How Does Global and Professional Direct Contracting (GPDC) Affect Risk Adjustment?
July 15th, 2021 - Aimee Wilcox, CPMA, CCS-P, CST, MA, MT, Director of Content
CMS recently announced the 53 Direct Contracting Entities (DCEs) that will be participating in the April 1, 2021 through December 31, 2021 Global and Professional Direct Contracting (GPDC) Model. Among those participating is Clover Health Partners, who runs an in-home primary care program that has the potential to help Medicare ...

Home About Contact Terms Privacy

innoviHealth® - 62 E 300 North, Spanish Fork, UT 84660 - Phone 801-770-4203 (9-5 Mountain)

Copyright © 2000-2021 innoviHealth Systems®, Inc. - CPT® copyright American Medical Association